Jim Cramer, host of Mad Money, recently discussed some of the significant challenges the alcohol industry is facing. He pointed out that as the end of January approaches, the wine and spirits industry ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...

Ozempic and Wegovy are increasingly available in Australia and worldwide to treat type 2 diabetes and obesity. The dramatic ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

A new study has examined the effects of GLP-1 drugs on 175 different health outcomes. ​​​While these drugs have been found to ...